Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Any comments on this?
Family-Friendly High-Tech Toys
January 6, 2007 - Chris Byrne, The Toy Guy, shows the best, most visual and unique hi-tech "toys", gadgets and games for both kids and adults featured at the International Consumer Electronics Show in Las Vegas.
Chris is known for his appearances on the "Today" show and other programs demonstrating the latest toys and games and having tons of fun while doing so. He approaches CES with a unique perspective, hi-tech products that are family-friendly and just plain fun and he's available via satellite to share that perspective with viewers.
For more information about Chris, visit toyguy.com
Some of the Products featured during the interview
WowWee's Roboquad : Four-legged intelligent life form with extraordinary multidirectional movement capabilities and advanced sensory awareness. Roboquad has a ubiquitous travel platform that allows him to move in any direction, even up and down at 3 different speeds. Roboquad's large beedy eyes put out a focused IR beam that reflects against his world so he can make smart decisions on where things are and where he can go. Roboquad has the ability to spot movements at up to 13 feet. His fast scanning head allows him to see sizes, edges, even doorways and make quick decisions about his actions. Roboquad reacts quickly to sounds and will scan its environment for any possible intrusion.
Ages: 8 and up Available: Fall 2007 Retail: $119
Presto Service and HP Printing: Technology-savvy consumers will be able to share digital content, including email and photos, with family and friends who don't have a computer or Internet connection. According to a recent Pew Internet & American Life survey, nearly 65 million American adults are not online and only 26 percent of Americans age 65 and older go online. The HP Printing Mailbox is a printer that hooks into an ordinary phone line, without the need for a computer or Internet connection and regular calls won't be interrupted. The Presto Service delivers email, photos and more from any email program, mobile phone or PDA to the HP Printing Mailbox. The Presto Service converts the digital content into beautiful color printouts, which the HP Printing Mailbox automatically retrieves and prints on a daily schedule.
The Presto Service is now available for $9.99 monthly or $99.99 yearly at Presto.com or by calling toll-free 1-800-919-3199. The HP Printing Mailbox is available for $149.99 direct from Presto and from a variety of online retailers, including Amazon.com, BestBuy.com, and Buy.com, as well as popular catalogs such as Hammacher-Schlemmer and SkyMall.
Fisher-Price Easy-Link Internet Launchpad: Kids can safely and easily visit preschool appropriate websites to play their favorite online games without getting into their parents computer files. Parents simply connect the Easy-Link Launchpad to their computer via a USB cord. Then kids can plug their favorite characters into the Launchpad, and be taken directly to that website no typing or reading required! (For example, plug in the Elmo figure to be taken directly to the games section of sesamestreet.com.). Kids can only visit a website of the character, keeping them away from unsafe websites.
Age: 3 years and up Price: $29.99 Avail: July 2007.
KeepSafe: A biometric security product that affords you a level of security unavailable prior to this product's release. KeepSafe 2.0 does not require any type of key or combination that can be tampered with, it is controlled entirely by your one of a kind fingerprint. KeepSafe 2.0 is the ultimate solution for your storage and/or protection needs for valuable items including: jewelry, weapons, ammunition, critical personal or professional data or documents, pharmaceuticals, stamps, stocks/bonds and anything you want to protect.
Dimension: 12.5" wide x 17.75" long x 6" deep. For more info: http://cyberkeysolutions.com
More about the the International Consumer Electronics Show:
The International Consumer Electronics Show (CES) is the world's largest annual tradeshow for consumer technology and America's largest annual trade show of any kind. The CES features nearly 2,700 exhibitors, filling 1.6 million net square feet of exhibit space -- CES showcased its latest products and services to more than 140,000 attendees at the 2006 International CES.
For more information about the International Consumer Electronics Show, visit www.cesweb.org
Family-Friendly High-Tech Toys
January 6, 2007 - Chris Byrne, The Toy Guy, shows the best, most visual and unique hi-tech "toys", gadgets and games for both kids and adults featured at the International Consumer Electronics Show in Las Vegas.
Chris is known for his appearances on the "Today" show and other programs demonstrating the latest toys and games and having tons of fun while doing so. He approaches CES with a unique perspective, hi-tech products that are family-friendly and just plain fun and he's available via satellite to share that perspective with viewers.
For more information about Chris, visit toyguy.com
Some of the Products featured during the interview
WowWee's Roboquad : Four-legged intelligent life form with extraordinary multidirectional movement capabilities and advanced sensory awareness. Roboquad has a ubiquitous travel platform that allows him to move in any direction, even up and down at 3 different speeds. Roboquad's large beedy eyes put out a focused IR beam that reflects against his world so he can make smart decisions on where things are and where he can go. Roboquad has the ability to spot movements at up to 13 feet. His fast scanning head allows him to see sizes, edges, even doorways and make quick decisions about his actions. Roboquad reacts quickly to sounds and will scan its environment for any possible intrusion.
Ages: 8 and up Available: Fall 2007 Retail: $119
Presto Service and HP Printing: Technology-savvy consumers will be able to share digital content, including email and photos, with family and friends who don't have a computer or Internet connection. According to a recent Pew Internet & American Life survey, nearly 65 million American adults are not online and only 26 percent of Americans age 65 and older go online. The HP Printing Mailbox is a printer that hooks into an ordinary phone line, without the need for a computer or Internet connection and regular calls won't be interrupted. The Presto Service delivers email, photos and more from any email program, mobile phone or PDA to the HP Printing Mailbox. The Presto Service converts the digital content into beautiful color printouts, which the HP Printing Mailbox automatically retrieves and prints on a daily schedule.
The Presto Service is now available for $9.99 monthly or $99.99 yearly at Presto.com or by calling toll-free 1-800-919-3199. The HP Printing Mailbox is available for $149.99 direct from Presto and from a variety of online retailers, including Amazon.com, BestBuy.com, and Buy.com, as well as popular catalogs such as Hammacher-Schlemmer and SkyMall.
Fisher-Price Easy-Link Internet Launchpad: Kids can safely and easily visit preschool appropriate websites to play their favorite online games without getting into their parents computer files. Parents simply connect the Easy-Link Launchpad to their computer via a USB cord. Then kids can plug their favorite characters into the Launchpad, and be taken directly to that website no typing or reading required! (For example, plug in the Elmo figure to be taken directly to the games section of sesamestreet.com.). Kids can only visit a website of the character, keeping them away from unsafe websites.
Age: 3 years and up Price: $29.99 Avail: July 2007.
KeepSafe: A biometric security product that affords you a level of security unavailable prior to this product's release. KeepSafe 2.0 does not require any type of key or combination that can be tampered with, it is controlled entirely by your one of a kind fingerprint. KeepSafe 2.0 is the ultimate solution for your storage and/or protection needs for valuable items including: jewelry, weapons, ammunition, critical personal or professional data or documents, pharmaceuticals, stamps, stocks/bonds and anything you want to protect.
Dimension: 12.5" wide x 17.75" long x 6" deep. For more info: http://cyberkeysolutions.com
More about the the International Consumer Electronics Show:
The International Consumer Electronics Show (CES) is the world's largest annual tradeshow for consumer technology and America's largest annual trade show of any kind. The CES features nearly 2,700 exhibitors, filling 1.6 million net square feet of exhibit space -- CES showcased its latest products and services to more than 140,000 attendees at the 2006 International CES.
For more information about the International Consumer Electronics Show, visit www.cesweb.org
I donot know Spianish. But this is not America. This is a public board for everyone who speaks not only english but other languages too. So pls donot not assume the whole world should spin around America.
Merck and Chi-Med start anti-cancer drug collaboration
By Staff Reporter
20/11/2006 - Merck and Chi-Med have announced the start of their collaboration, which aims to discover novel small molecule anti-cancer drugs derived from natural products that modulate oncological pathways.
It's a new direction for the pharmaceutical giants, who have teamed up with Chi-Med, a company that uses traditional Chinese medicine as an under-exploited reservoir for the development of novel drugs for the global pharmaceutical market.
Plants, particularly those that have been used as traditional medicines, have a long-established record of efficacy and safety.
Under the terms of the agreement, the primary goal is to leverage the expertise of both Merck and Chi-Med in oncology research. Financial details of the collaboration were not disclosed.
This collaboration will also be an opportunity to address important unmet medical needs by accessing natural products, a rich source of diversified chemical components with drug-like properties.
“Over the last four years, we have established a solid R&D organization that has brought two candidates into US phase II clinical studies in the oncology and auto-immune areas,” said Christian Hogg, CEO of Chi-Med.
“We are delighted to partner with Merck to broaden our research activities in the oncology area. Merck has a good record of achievement in the development and commercialisation of oncology products such as Erbitux. In addition, we believe this collaboration further validates Chi-Med's drug discovery capability."
From 1999 to 2004 the Chinese pharmaceutical market grew at a compound annual growth rate ("CAGR") of 20 per cent from $15.1bn (€11.8bn) to $37.2bn.
The company currently has two candidates in clinical development in both the US and China.
HMPL-002, a radiosensitiser for head and neck and non-small cell lung cancer (NSCLC), is in Phase I/II in the US and in proof of concept in China. HMPL-004, an inhibitor to a group of inflammatory cytokines, for treatment of inflammatory bowel diseases, including Crohn's Disease and Ulcerative Colitis, is in Phase II in the US and in proof of concept in China.
“We are delighted to complement and enrich our oncology research with this collaboration. It will also allow us to extend our interaction with the emerging Chinese pharmaceutical industry that builds on the long-standing tradition and knowledge of Traditional Chinese Medicine combined with modern scientific technology,” said Dr. Ulrich Betz, Preclinical R&D, Head of Strategic Innovation and Research Portfolio Management for Merck.
“We are looking forward to a productive collaboration with Chi-Med.”
Contact chinese for promotion
The fact that Nicosan is a herbal medicine ia s double-edge sword. Normally, a herbal medicine does not have a well-defined chemical strcture since it is a extract. This can hurt in terms of FDA approval (just my opinion). A herbal medican, on the other hand, has less chance to be toxic to human. Chinese herbal medicines have been used for 2-3 thousand yrs and proved to be especially effective for chronic diseases. Since chinese herbal medicines normally donot undergo strict safety tests before approved in China, it is very hard for them to be approved to be used in America. I guess some chinese organizations might be glad to see the first herbal FDA approval in US, e.g., Nicosan. If someone here has connections with chinese organizations, it may be a good idea to let thme know about Nicosan. They may help promote Xechem one way or another.
0.1 on Chart II?
Donot get upset if u really have that many shares. Like I said before, this is like gambling. The good thing is that you may have a chance to get your money back by investing in Xechem even with a huge gain. Gambling in casinos wont give you that chance or hope. If u lose, u lose, period.
Anyone who is expecting a OTC to become $5 stock overnight is daydreaming.
Anyone who is calling Xechem a scam without proof is a basher.
Anyone who is posting positive-only posts is a pumper who bought @super low and want to sell for a profit
Anyone who rarely posts but read posts on this board is a serious investor
All longs on OTC are gamblers like me. We may get rewarded dearly, but things can go other way.
Xechem is worth gambling. I will still have my normal life even if I lose all my investment in this baby. No big deal.
Cant agree more.
Many so-called longs here post tons of speculations everyday. If you are really longs, pls just post whatever infos you obtained in whatever ways. Xeckem is a long held investment even if it will become a big star.
If you are worried about day-to-day fluctations, you are not longs as you claimed to be.
I am reading posts here because I want to buy more at the right price at the right time. Otherwise I will just go away and come back in one or more yrs.
Investment in OTC is a gamble (an educated one) at the best. If you bet wrong, norammly you wont lose a lot (even u you a multi-M shares, still it is no big deal in terms of loss). If you bet right you can retire early. As simple as that.
Lets just post meaningful info for potentail new investors. The more people are getting interested, the better chance we will have when Xechem is doing really well.
Of course if you are a fake longs, forget about what I just said
Stop writing in Capital, will u?
Regarding the email
I donot know if the nigerian gentleman just got info from web or from his first-hand experiences. If someone here come acros the same stuff described in his (her)email on line, pls let me know. Having said that, 2 things in his email impressed me (1) Nicosan was originally developed by a traditional Nigerian medicine practionor (how many people here knew about this? at least I did not know) and (2) he offered to buy it as middleman for my friend.
I have no idea. I just copied the email here. If you guys donot believe, I can give his email address to you. Actually, the nigerian guy has a blog online. My friend emailed him through his blog.
The email you guys may want to read
From : <erased>
Sent : Saturday, November 11, 2006 6:38 PM
To : <erased>
CC : <erased>
Subject : Re: There are drugs for sickle-cell in Nigeria
|
|
| folder1
| Inbox
Dear Paschal,
I really appreciate your reply. The info you provided will be very helpful for my friend. I will forward your message to my friend.
Thank again for your help
God less you
John
On Sat, 11 Nov 2006 08:31:19 -0800 (PST) paschal chuma <passyjango@yahoo.com> writes:
Hi John,
Sorry for the slight delay in responding to your e-mail. There are a number of drugs for sickle-cell disease in Nigeria.However of all these drugs one stands out as the champion. This is a drug called Nicosan.
Nicosan(formally known as Niprisan) was developed by a team of reseachers at Nigeria's National Institute for Pharmaceutical Research and Development(NIPRD) with the help of a traditional medicine practitioner. Nicosan is a mixture of extracts from four tropical plants that grow in the wild in Nigeria.
However, the right to patent for the drug was sold to a US based company Xechem international inc. The company now has a production facility in Nigeria which was launched this year.
Nicosan is an anti-sickling natural herbal drug for the management of sickle-cell disease.Although Nicosan is not a cure for sickle-cell, it has been shown that majority of patient using Nicosan no longer experience crisis while on the medication.Also those whose crisis are not elliminated the crisis is substantially reduced.
The drug is taken through one-a-day capsules which, once started, must be taken daily by the patient. The current price for a months supply for Adults is about N 4,000 Naira (approx. US $32) and for Pediatrics about N 3,100 Naira (approx. US $24), respectively.
As for how you can get hold of the drug, there are two options.The first option is to find out whether the drug is sold online. Option 2, which is the only option if option one is not possible is that I will be the middleman between you and the company. This means we calculate the cost, you send the money, I buy the product and send it to the address that you provide(by the way I dont know where you are writing from).
I think I will stop here, I hope the information provided will be helpful.bye for now.
Paschal,
My friend forwarded an email to me over the weekend. It was his email exchange between him and a native Nigerian regarding SID and Nicosan. Very interesting to read. Since it was personal mail, I donot want to post it here. I will ask my friend if it is ok though.
he got 27 after mine
No, I bought @0.17 for the same shares I bought @0.02 now
Pandey should change the company's name for the following reasons:
1. Xechem is hard to pronunate
2. Xe stands for Xenon, an INACTIVE chemical element
3. Chem makes Xechem sound like a chemical company, not a drug company.
I believed i have learned some lessons regatding stocks. I still believe in Xechem though.
0.17 not 0.017
I donot even remember when i bought it. I got some cash back then and I wanted to dive into stocks for the first time. So I searched all penny stocks in 0.1-1.0 ranges. There you go. I found XKEM (ZKEM then?). SO I bought. And never even bothered to check the price.
Here I am back.
questions for you guys:
If all of you are real longs as you claim, why you guys care about day-to-day variations in the 0.02s ranges?
Some of you got millinons's shares, what would you do if share prices hit, say, $1-2? Would yuo be tempted to sell becuase you are already rich if you can unload at the price ranges? If all of you do this, how can the price hold there?
BTW, I am really a true long, I bought a lot @ 0.17 and even did not look at the price for 2 yrs. I am buying more now. I will hold until I can retire on this thing.
The picture looks very un-impressive. They should not post such a picture. I am in the chemical industry (not in drug manufacturing, but close enough). The foundation in the picture does not look like for a real modern chemical manufacturing facility. But I can be wrong considering the observation that Nigera can not have tall builidings for some reason.
Xechem is a real thing, no doubt about it. What is stopping Xechem from becoming a big star is perhaps that Xechem gives potential investors an impression that it is a family business. It seems to me (again I could be wrong) that all top guys in Xechem are from the Pandey family. This is very bad in investors' eyes (at least in my eyes).
In addition, the fact that the Pandey family is Indian does not give a positive impression either (sorry I am not against indians). The top management in Xechem should include more guys from other ethics.
Liquid, I havent got it. Please send to hp_wu00@hotmail.com
tks
Pls send me to hp_wu00@hotmail.com. Tks in advance
I donot post much and I donot know how Xechem will fare. But one thing I donot understand about fat is: why you waste your time here posting if you hate Xechem? Go somewhere else to kill time pls
As far as I know, the drug is an extract from 4 herbs (seeds leaf, stem, etc.). The question that should but has never been asked before here is what are the harvest seasons for those 4 things? If they are not harvested in the same season, how are they stored? or can they be stored for a long time?
The answer to the question might shed some light on if Xechem has problem dealing with this issue if there is one.
I was trying to find out online exactly how the drug is made, but without much success. It seems to me the extraction process is very easy once you got all the raw materials (herbs)in stock.
I donot understand why it took Xechem so many years to go to full production.
Can you pls tell me what restriction Sccottrade has right now?
I am using it also.
Drug discovery through ethnobotany in Nigeria: some results. Okogun, Joseph I. National Institute for Pharmaceutical Research and Development, Abuja, Nigeria. Advances in Phytomedicine (2002), 1(Ethnomedicine and Drug Discovery), 145-154. Publisher: Elsevier Science B.V., CODEN: APDHB8 Journal; General Review written in English. CAN 139:206817 AN 2003:104632 CAPLUS
Abstract
A review. Ethnobotany and ethnomedicine are as old as man's history. The combination of ethnobotany and ethnomedicine is a popular research field in Nigeria that, unfortunately, has not led to the prodn. of many market products. The plant Zanthoxylum zanthoxyloides (Lam). Zepernich & Timter (Rutaceae) is used in ethnomedicine for a no. of ailments. The exts. of the plant contain a wide variety of secondary metabolites assocd. with a no. of biol. activities. The active principles in its exts. responsible for its antisickling effect have been identified, and the synthetic conversion of one of its metabolites yielded the antisickling acid, DBA. With assistance from various organizations, NIPRISANR, a herbal drug of ethnomedicine source that is used for sickle cell anemia disorder, is in its third clin.-trial development phase at the National Institute for Pharmaceutical Research and Development, Abuja, Nigeria.
Indexing -- Section 1-0 (Pharmacology)
Biology
(botany, ethnobotany; drug discovery through ethnobotany in Nigeria)
Drugs
Human
Human groups
Sickle cell anemia
(drug discovery through ethnobotany in Nigeria)
Natural products, pharmaceutical
Role: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug discovery through ethnobotany in Nigeria)
Medicine
(ethnomedicine; drug discovery through ethnobotany in Nigeria)
Supplementary Terms
review drug discovery ethnobotany
Citations
1) Anon; Bitter water made sweet with a piece of wood inspired by Moses: Exodus, 8th edition, 15, 22
1) Anon; Merck Index, 8th edition
2) Klayman, D; Science 1985, 228, 1049
3) Farnsworth, N; New natural products and plant drugs with pharmacological, biological or therapeutical activity 1977
4) Clark, A; Pharmaceut Res 1996, 13, 1133
4) Wambebe, C; Paper presented at the 21st Annual Conference of the Chemical Society of Nigeria 1998
5) Farnsworth, N; Ciba Found Symp 1990, 154, 2
6) Schlitter; The alkaloids 1965, 8, 287
7) Mann, J; Murder, magic and medicine 1992, 31
8) Harley-Mason, J; J Chem Soc 1954, 3651
9) Woodward, R; J Am Soc 1945, 67, 860
10) Andersag, H; Chem Ber 1948, 81, 499
11) American Pharmaceutical Association and Pharmaceutical Society of Great Britain; Handbook of pharmaceutical excipients 1983, 1
12) Coursey, D; Yams: an account of the nature, origins, cultivation, and utilisation of the useful members of Dioscoreaceae 1967
13) Sofowora, A; Proceedings of a conference, coorganized with the Society of Pharmacology 1986, 16
14) Aladesanmi, A; Proceedings of the annual conference of the Nigerian Society of Pharmacognosy 1990
15) Iwu, M; Handbook of African medicinal plants 1993
16) Sofowora, A; Medicinal plants and traditional medicine in Africa 1992
17) Okogun, J; Proc Nigerian Acad Sci 1985, 29
18) Akubue, P; Proceedings of a conference co-organized with the Society of Pharmacology 1986, 53
19) Iwu, M; J Nat Prod 1982, 45, 650
20) Iwu, M; First symposium on plant flavonoids in biology and medicine 1985
21) Igboko, O; J Pharm Res Dev 1986, 364
22) Okor, R; Applications of some selected natural products as excipients for dosage formulation 1990, 15
23) Abdurahman, E; J Pharm Res Dev 1996, 1, 49
24) Eka, O; Nigerian J Nutr Sci 1980, 1, 33
25) Patel, C; J Sci Fd Agr 1950, 1, 45
26) Abaelu, A; Nigerian J Nutr Sci 1980, 1, 133
27) Udeala, O; J Pharm Pharmacol 1980, 32, 6
28) Adikwu, M; J Pharm Res Dev 1997, 2, 42
29) Ohiri, F; J Pharm Res Dev 1997, 2, 11
30) Nasipuri, R; J Pharm Res Dev 1997, 2, 27
31) Dalziel, J; The useful plants of West Tropical Africa, 2nd edition 1955
32) Gbile, Z; Nigerian J Sci 1975, 9, 337
33) Thoms, H; Chem Ber 1911, 44, 3717
34) Paris, M; Ann Pharm France 1947, 5, 412
35) Carnmalm, B; Acta Chem Scand 1955, 9, 1118
36) Bowden, K; Ann Pharm Franc 1963, 5, 410
37) Eshiet, I; PhD thesis, University of Ibadan 1967
38) Eshiet, I; J Chem Soc 1968, 481
39) Messmer, W; J Pharm Sci 1972, 61, 1858
40) Sofowora, E; Lloydia 1971, 38, 169
41) Honig, G; Lloydia 1975, 38, 387
42) Honig, G; Nature 1978, 272, 833
43) Enyenihi, V; PhD thesis, University of Ibadan 1975
44) Ayafor, J; PhD thesis, University of Ibadan 1978
45) Okogun, J; Nigeria J Sci 1978, 12, 589
46) Elujoba, A; Plant Medica 1977, 32, 54
46) Sofowora, E; Lloydia 1975, 38, 169
47) Elujoba, A; Nigerian J Pharm 1984, 15, 281
48) Elujoba, A; J Pharm Biomed Anal 1985, 3, 447
49) Elujoba, A; Int J Pharmaceut 1989, 53, 1
50) Fatope, O; J Chem Soc Perkin 1982, 1, 1601
51) Bonner, T; J Chem Soc B 1968, 795
52) Ekong, D; Nature 1975, 258, 743
53) Okpako, D; Planta Medica 1983, 47, 112
54) Essien, E; Thrombosis and Haemostatis 1976, 26, 525
55) Essien, E; African J Med Sci 1985, 14, 83
56) Sieve, B; Science 1952, 116, 273
57) Manwaring, D; Phytochemistry 1968, 7, 1881
58) Oriowo, M; PhD thesis, University of lbadan 1979
59) Awodogan, A; J Pharm Res Drug 1966, 2, 39
60) Gamaniel, K; J Pharm Res Dev 1998, 3, 89
Efficacy of niprisan in the prophylactic management of patients with sickle cell disease. Wambebe, Charles O.; Bamgboye, Elijah Afolabi; Badru, Bidemi O.; Khamofu, Hadiza; Momoh, Jafaru A.; Ekpeyong, Margaret; Audu, Benedict S.; Njoku, Simon O.; Nasipuri, Nathaniel R.; Kunle, Olubayo O.; Okogun, Joseph I.; Enwerem, Nkechi M.; Gamaniel, Shingu K.; Obodozie, Oby O.; Samuel, Babatunde; Fojule, Gloria; Ogunyale, Paul O. National Institute for Pharmaceutical Research and Development, Abuja, Nigeria. Current Therapeutic Research (2001), 62(1), 26-34. Publisher: Excerpta Medica, Inc., CODEN: CTCEA9 ISSN: 0011-393X. Journal written in English. CAN 135:162254 AN 2001:136276 CAPLUS
Abstract
Niprisan is a new drug extd. from indigenous herbs that has been developed by the Nigerian National Institute for Pharmaceutical Research and Development for the prophylactic management of patients with sickle cell disease. The objective of this study was to assess the efficacy and tolerability of niprisan in the management of patients with sickle cell disease. This was a randomized, double-blind, placebo-controlled, crossover trial. Patients who met the criteria for homozygous sickle cell disease and had 3 painful or vaso-occlusive crises per yr were randomized to 1 of 2 study groups. Group A took niprisan 12 mg/kg body wt. for 6 mo before crossing over to placebo for another 6 mo; group B took placebo for 6 mo before crossing over to niprisan for another 6 mo. There was a 1-mo washout period before the crossover. The main outcome measures were the incidence of crises; the occurrence of painful episodes; certain clin., hematol., and biochem. measures; and patients' daily self-assessment of health. Eighty-four patients met the inclusion criteria, but complete data were available for only 69 patients at the end of 12 mo, 33 in group A and 36 in group B. Loss to follow-up was related to social and logistic factors rather than study drug. One oral dose of 12 mg/kg niprisan daily significantly reduced the frequency of sickle cell crises, bone pain, and hospital admission (P < 0.05). The mean no. of crises per person per mo was 0.05 in patients who received niprisan initially, compared with 0.11 per person per mo after the crossover to placebo. Patients generally rated their health as better and reported less sickness and absenteeism with niprisan than with placebo. Apart from headache, which was reported by 9 patients while taking niprisan, there were no important adverse effects. Niprisan was efficacious in the prophylactic management of patients with sickle cell disease, although addnl. confirmatory studies in larger sample sizes are needed.
Indexing -- Section 1-8 (Pharmacology)
Sickle cell anemia
(efficacy of niprisan in prophylactic management of patients with sickle cell disease)
Natural products, pharmaceutical
Role: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(niprisan; efficacy of niprisan in prophylactic management of patients with sickle cell disease)
Supplementary Terms
niprisan sickle cell disease management
Citations
1) Jelife, D; Br Med J 1952, 1, 405
2) Akinyanju, O; Ann NY Acad Sci 1989, 565, 126
3) Adedoyin, M; East Afr Med J 1992, 69, 370
4) Oyedeji, G; East Afr Med J 1991, 68, 181
5) Howard, L; Ann Pharmacother 1997, 31, 1393
6) Charache, S; N Engl J Med 1995, 332, 1317
7) Ohene-Frempong, K; Semin Hematol 1997, 34, 30
8) Adekile, A; Nigerian Med J 1990, 20, 44
9) Gamaniel, K; J Pharm Res Dev 1998, 3, 89
10) Walonick, D; StatPac Gold-Statistical Analysis Package for the IBM 1988
11) Murtaza, L; Br Med J 1981, 282, 1048
12) Charache, S; Medicine 1996, 75, 300
n vitro effects of NIPRISAN (Nix-0699): a naturally occurring, potent antisickling agent. Iyamu, Efemwonkiekie W.; Turner, Ernest A.; Asakura, Toshio. Division of Hematology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA. British Journal of Haematology (2002), 118(1), 337-343. Publisher: Blackwell Science Ltd., CODEN: BJHEAL ISSN: 0007-1048. Journal written in English. CAN 137:195307 AN 2002:631927 CAPLUS
Abstract
Among the various potential antisickling agents tested, hydroxyurea (HU) has been the most effective compd. used for the treatment of patients with sickle cell disease (SCD). Although HU is effective in many patients, not all patients respond to this drug. In addn., some patients reveal adverse effects, including myelosuppression. In an attempt to find other effective agents with less adverse effects, we investigated the antisickling effect of NIPRISAN (Nix-0699). We found that Nix-0699, an ethanol/water ext. from indigenous plants, has a strong antisickling effect. The concn. of Nix-0699 required to inhibit 50% of erythrocyte sickling was about 0.05 mg/mL. As for the kinetics of polymn., addn. of 0.05 g/mL Nix-0699 caused a sixfold prolongation of the delay time prior to deoxy-Hb S polymn. when compared with that of untreated Hb S samples. The soly. of deoxy-Hb S significantly increased upon treatment with Nix-0699. Anal. of the effect of Nix-0699 on the Hb S oxygen affinity indicated that the drug slightly shifted the oxygen-dissocn. curve of Hb S toward the left without any apparent change in the Hill coeff. These results suggest that the antisickling properties of Nix-0699 may involve direct interaction with Hb mols. Incubation of red blood cell (RBC) suspensions with various concns. of Nix-0699 did not dehydrate RBCs, cause hemolysis, increase the amt. of denatured Hb, nor form met-Hb. In view of the outcome of this study, Nix-0699 may be a promising option for the treatment of patients with SCD.
Indexing -- Section 1-8 (Pharmacology)
Hypoxia
(in vitro effects of NIPRISAN (Nix-0699) naturally occurring, potent antisickling agent effect on blood of sickle cell anemia patients: effect of drug on sickle cell under hypoxic condition)
Blood analysis
(in vitro effects of NIPRISAN (Nix-0699) naturally occurring, potent antisickling agent effect on blood of sickle cell anemia patients: effect of drug on soly. of deoxy-Hb S)
Erythrocyte
Hemolysis
(in vitro effects of NIPRISAN (Nix-0699) naturally occurring, potent antisickling agent effect on blood of sickle cell anemia patients: rate of hemolysis, formation of met-Hb, size of RBC, and level of MADH)
Hemoglobins
Hemoglobins, methemoglobins
Role: BSU (Biological study, unclassified); BIOL (Biological study)
(in vitro effects of NIPRISAN (Nix-0699) naturally occurring, potent antisickling agent effect on blood of sickle cell anemia patients: rate of hemolysis, formation of met-Hb, size of RBC, and level of MADH)
Human
Sickle cell anemia
(in vitro effects of NIPRISAN (Nix-0699): naturally occurring, potent antisickling agent effect on blood of sickle cell anemia patients)
Natural products, pharmaceutical
Role: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in vitro effects of NIPRISAN (Nix-0699): naturally occurring, potent antisickling agent effect on blood of sickle cell anemia patients)
Embryophyta
(medicinal plant; in vitro effects of NIPRISAN (Nix-0699): naturally occurring, potent antisickling agent effect on blood of sickle cell anemia patients)
376643-51-5, NIPRISAN
Role: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Nix 0699; in vitro effects of NIPRISAN (Nix-0699): naturally occurring, potent antisickling agent effect on blood of sickle cell anemia patients)
7782-44-7, Oxygen, biological studies
Role: BSU (Biological study, unclassified); BIOL (Biological study)
(in vitro effects of NIPRISAN (Nix-0699) naturally occurring, potent antisickling agent effect on blood of sickle cell anemia patients: detn. whether antisickling property is attributed to left-shift of blood-oxygen dissocn. curve)
9035-22-7, Hemoglobin S
Role: BSU (Biological study, unclassified); BIOL (Biological study)
(in vitro effects of NIPRISAN (Nix-0699) naturally occurring, potent antisickling agent effect on blood of sickle cell anemia patients: effect of drug on soly. of deoxy-Hb S)
Supplementary Terms
herb natural product Nix0699 Hb soly sickle cell anemia
Citations
Abraham, D; Approaches to the Therapy of Sickle Cell Anemia 1986, 141
Adachi, K; Journal of Biological Chemistry 1978, 253, 6641
Adachi, K; Journal of Biological Chemistry 1979, 254, 4079
Adachi, K; Journal of Biological Chemistry 1979, 254, 7765
Adachi, K; Blood Cells 1982, 8, 213
Al-khatti, A; Blood 1988, 72, 817
Asakura, T; Critical Care Medicine 1979, 7, 391
Asakura, T; Journal of Clinical Investigation 1977, 59, 633
Ballas, S; Sickle Cell Disease: Basic Principle and Clinical Practice 1994
Beutler, E; Blood 1975, 46, 253
Beutler, E; Journal of Clinical Investigation 1961, 40, 1857
Charache, S; Blood 1992, 79, 2555
Charache, S; New England Journal of Medicine 1995, 332, 1317
Eaton, W; Advances in Protein Chemistry 1990, 40, 63
Festa, R; Transfusion 1979, 19, 107
Fibach, E; Blood 1993, 81, 1630
Horiuchi, K; Journal of Laboratory and Clinical Medicine 1990, 115, 613
Laszlo, J; South Medical Journal 1969, 62, 453
Ley, T; Blood 1991, 77, 1146
Orringer, E; Sickle Cell Disease: Basic Principle and Clinical Practice 1994
Perrine, S; New England Journal of Medicine 1993, 328, 81
Sunshine, H; Nature 1978, 275, 238
Wambebe, C; Phytomedicine 2001, 8, 252
Wambebe, C; Current Therapeutic Research 2001, 62, 26
nvestigational agents for sickle cell disease. Okpala, Iheanyi. St Thomas' Hospital, University of London, London, UK. Expert Opinion on Investigational Drugs (2006), 15(8), 833-842. Publisher: Informa Healthcare, CODEN: EOIDER ISSN: 1354-3784. Journal; General Review written in English. CAN 145:240787 AN 2006:722229 CAPLUS
Abstract
A review. Developments in the treatment of sickle cell disease (SCD) have not kept pace with advances in understanding the pathophysiol. of this haemoglobinopathy. Drugs undergoing preclin. and clin. assessment for the therapy of these globin gene disorders are discussed in this article. Beginning with investigational agents for treatment of SCD as a whole, the discussion proceeds to drugs being developed for specific manifestations or iatrogenic complications. Despite being licensed in the USA, the prototype antisickling agent, hydroxycarbamide, has not attained worldwide clin. use because of concerns about long-term toxicity. The less toxic decitabine, which (as with hydroxycarbamide) increases fetal Hb level, cannot be administered orally; therefore, the search continues for effective and safe antisickling drugs that can be taken orally. The naturally occurring benzaldehyde 5-hydroxymethyl-2-furfural has shown promising antisickling properties in vitro, and when administered to transgenic sickle mice. These effects are surpassed by the new synthetic pyridyl derivs. of benzaldehyde. Studies in humans with SCD are required to assess the clin. efficacy of these benzaldehydes. Niprisan, another antisickling agent with significant clin. efficacy and an attractive safety profile, is undergoing further development. The prospects of antiadhesion therapy in SCD are demonstrated by a recombinant protein contg. the Fc fragment of IgG fused to the natural ligand for selectins: the conjugate significantly inhibited blood vessel occlusion in transgenic sickle mice. Whereas the orally administrable iron-chelating agent deferasirox is likely to increasingly take the place of desferrioxamine (which can only be given parenterally), effective treatment of priapism in SCD remains a distressing challenge.
Indexing -- Section 1-0 (Pharmacology)
Human
Sickle cell anemia
(investigational agents for sickle cell disease)
127-07-1, Hydroxycarbamide
Role: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(investigational agents for sickle cell disease)
67-47-0, 5-Hydroxymethyl-2-furfural
2353-33-5, Decitabine
201530-41-8, Deferasirox
376643-51-5, Niprisan
Role: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(investigational agents for sickle cell disease)
Supplementary Terms
review sickle cell disease therapy drug
Citations
1) Ingram, V; Nature 1957, 180, 326
2) Okpala, I; Practical management of haemoglobinopathies 2004, 20
3) UNESCO; Report of Commission II, General Conference, 33rd Session 2005
4) Konotey-Ahulu, F; Ghana Med J 1968, 7, 118
5) Onwubalili, J; Lancet 1983, 322, 503
6) Africanus Horton, J; The diseases of tropical climates and their treatment 1874
7) Herrick, J; Arch Intern Med 1910, 6, 517
8) Okpala, I; Hematol Oncol Clin N Am 2005, 19, 975
9) Stuart, M; Lancet 2004, 364, 1343
10) Charache, S; Semin Hematol 1997, 34, 15
11) Cokic, V; J Clin Invest 2003, 111, 231
12) Styles, L; Blood 1997, 89, 2554
13) Hillery, C; Br J Haematol 2000, 109, 322
14) Steinberg, M; J Am Med Assoc 2003, 289, 1645
15) Johnston, R; N Engl J Med 1973, 288, 803
16) Pearson, H; Ann NY Acad Sci 1989, 565, 120
17) Mollapour, E; Blood 1998, 91, 3423
18) Anyaegbu, C; Eur J Haematol 1998, 60, 267
19) Saunthararajah, Y; Blood 2003, 102, 3865
20) Abdulmalik, O; Br J Haematol 2005, 128, 552
21) Abdulmalik, O; Blood 2005, 106, 666a
22) Safo, M; J Med Chem 2004, 47, 4665
23) Abraham, D; Blood 1991, 77, 1334
24) Beddell, C; Br J Pharmacol 1984, 82, 397
25) Keidan, A; Nature 1986, 1, 831
26) Van-Gorsel, H; J Agric Food Chem 1992, 40, 784
27) Wambebe, C; Curr Ther Res 2001, 62, 26
28) Iyamu, E; Br J Haematol 2002, 118, 337
29) Iyamu, E; Br J Haematol 2003, 122, 1001
30) Wambebe, C; Phytomedicine 2001, 8, 252
32) Tan, P; Eur J Vasc Endovasc Surg 1999, 17, 373
33) Embury, S; Blood 2004, 104, 3378
34) von Adrian, U; Proc Natl Acad Sci USA 1991, 88, 7538
35) Okpala, I; Curr Opin Hematol 2006, 13, 40
36) Chiang, E; Hematol Oncol Clin N Am 2005, 19, 771
37) Kaul, D; Proc Natl Acad Sci USA 1989, 86, 3356
38) Okpala, I; Blood Rev 2004, 18, 65
39) Okpala, I; Eur J Haematol 2002, 69, 135
40) Okpala, I; Blood 2002, 100, 11a
41) Hebble, R; Microcirculation 2004, 11, 129
42) Kaul, D; Am J Physiol Heart Circ Physiol 2004, 287, H293
43) Belcher, J; Blood 2000, 96, 2451
44) McEver, R; Curr Opin Cell Biol 2002, 14, 581
45) Matsui, N; Blood 2001, 98, 1955
46) Hicks, A; Blood 2003, 101, 3249
47) Lew, V; Physiol Rev 2005, 85, 179
48) Steinberg, M; Semin Hematol 2001, 38, 299
49) de Franceschi, L; J Clin Invest 1994, 93, 1670
50) Stocker, J; Blood 2003, 101, 2412
51) Ataga, K; Blood 2004, 104, 33a
52) Sadelain, M; Curr Opin Hematol 2006, 13, 142
53) Puthenveetil, G; Curr Hematol Rep 2004, 3, 298
54) Hoppe, C; Curr Opin Oncol 2001, 13, 85
55) Amrolia, P; Br J Haematol 2003, 120, 725
56) Pawliuk, R; Science 2001, 294, 2368
57) Kohn, D; Nat Rev Cancer 2003, 3, 477
58) Sadelain, M; Gene Ther 2004, 11, 567
59) Ohene-Frempong, K; Semin Hematol 2001, 38, 5
60) The Investigators for ICL670 Study 109; Blood 2005, 106, 95a
61) Cabantchik, Z; Blood 2005, 106, 243a
62) Brissot, P; Blood 2005, 106, 242a
63) Cohen, A; Blood 2005, 106, 242a
64) Mantadakis, E; J Pediatr Hematol Oncol 1999, 21, 518
65) Lue, T; Campbell's Urology 2002, 8, 1591
66) Okpala, I; Br J Haematol 2002, 118, 918
67) Rogers, Z; Hematol Oncol Clin N Am 2005, 19, 917
68) Winter, C; J Urol 1988, 140, 980
69) Drugdex System; Etilefrine 2004, 122
70) Virag, R; Urology 1996, 47, 777
71) Gbadoea, D; Arch Dis Child 2001, 85, 52
72) Adeyoju, A; Br J Urology Int 2002, 90, 898
73) Okpala, I; Practical management of haemoglobinopathies 2004, 130
74) Castro, O; Hematol Oncol Clin N Am 2005, 19, 881
75) Castro, O; Hematol Oncol Clin N Am 1996, 10, 1289
76) Ataga, K; Am J Med 2004, 117, 665
77) Vicari, P; Am J Hematol 2005, 78, 160
78) Onyekwere, O; 28th Annual Meeting of the National Sickle Cell Program 2005
79) Wali, Y; Ann Trop Paediatr 2000, 20, 243
80) Johnson, C; Arch Intern Med 1981, 141, 891
81) Hammond, T; Arch Intern Med 1989, 149, 447
82) El-Beshlawy, A; Abstract Book of the 25th Meeting of the International Society of Haematology-African & European Division 1999, 120
83) Morris, C; Blood 2002, 100, 452a